Dyne Therapeutics Income Statement (2019-2026) | DYN

Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
51.61M51.61M51.67M51.74M51.91M55.64M58.31M61.01M61.32M61.47M87.09M100.12M101.75M102.32M113.63M114.34M142.61M128.44M165.20M165.67M
Operating items
Research & Development (Quarter)
36.51M42.30M28.24M46.66M34.67M33.19M37.54M59.13M55.25M58.84M44.54M62.26M92.80M81.81M106.45M99.24M97.22M95.43M100.89M152.17M
Selling, General & Administrative (Quarter)
6.26M9.66M7.55M6.09M7.61M6.96M7.93M7.61M7.02M8.84M24.62M9.70M12.86M15.30M15.93M16.55M16.67M20.70M24.39M29.49M
Other Operating Expenses (Quarter)
-0.01M-0.03M0.01M-0.01M-0.02M-0.22M-0.37M-0.13M-0.70M0.51M-0.19M-0.74M-0.03M-0.09M-1.60M0.28M-0.29M-0.13M-0.09M
Operating Expenses (Quarter)
42.77M51.96M35.78M52.76M42.28M40.15M45.46M66.74M62.27M67.69M69.16M71.96M105.66M97.11M122.37M115.79M113.89M116.13M125.28M181.66M
Operating Income (Quarter)
-42.77M-51.96M-35.78M-52.76M-42.28M-40.15M-45.46M-66.74M-62.27M-67.69M-69.16M-71.96M-105.57M-97.11M-122.37M-115.79M-113.89M-116.13M-125.28M-181.66M
EBIT (Quarter)
-42.77M-51.96M-35.78M-52.76M-42.28M-40.15M-45.46M-66.74M-62.27M-67.69M-69.16M-71.96M-105.57M-97.11M-122.37M-115.79M-113.89M-116.13M-125.28M-181.66M
Non-operating items
Interest & Investment Income (Quarter)
0.18M0.18M-0.66M-0.23M0.90M1.34M0.37M0.15M2.19M1.75M-0.13M-0.11M9.28M7.59M0.23M6.62M8.48M7.66M-0.61M7.79M
Other Non Operating Income (Quarter)
0.18M0.17M0.20M0.45M0.89M1.32M1.28M1.83M2.06M1.05M3.51M6.86M8.53M7.57M7.01M4.93M5.85M4.17M4.42M3.10M
Net income details
EBT (Quarter)
-103.26M-51.98M-62.52M-66.46M-83.92M-152.43M-77.32M-93.05M-75.59M-211.71M-202.78M-250.09M-96.29M-94.50M-128.69M-109.17M-108.32M-111.02M-175.27M-262.59M
Profit After Tax (Quarter)
-42.58M-52.02M-35.58M-52.30M-41.38M-38.41M-44.19M-64.90M-60.21M-66.64M-65.65M-65.10M-97.12M-89.54M-115.36M-110.86M-108.04M-111.95M-120.85M-178.77M
Income from Continuing Operations (Quarter)
-103.26M-51.98M-62.52M-66.46M-83.92M-152.43M-77.32M-93.05M-75.59M-211.71M-202.78M-250.09M-96.29M-94.50M-128.69M-109.17M-108.32M-111.02M-175.27M-262.59M
Consolidated Net Income (Quarter)
-103.26M-51.98M-62.52M-66.46M-83.92M-152.43M-77.32M-93.05M-75.59M-211.71M-202.78M-250.09M-96.29M-94.50M-128.69M-109.17M-108.32M-111.02M-175.27M-262.59M
Income towards Parent Company (Quarter)
-103.26M-51.98M-62.52M-66.46M-83.92M-152.43M-77.32M-93.05M-75.59M-211.71M-202.78M-250.09M-96.29M-94.50M-128.69M-109.17M-108.32M-111.02M-175.27M-262.59M
Net Income towards Common Stockholders (Quarter)
-103.26M-51.98M-62.52M-66.46M-83.92M-152.43M-77.32M-93.05M-75.59M-211.71M-202.78M-250.09M-96.29M-94.50M-128.69M-109.17M-108.32M-111.02M-175.27M-262.59M
Additional items
EPS (Basic) (Quarter)
-2.01-1.02-1.21-1.29-1.62-2.93-1.37-1.56-1.24-3.55-2.50-2.70-0.95-1.00-1.17-0.96-0.76-0.86-1.06-1.59
Shares Outstanding (Quarter)
51.32M50.90M51.60M51.68M51.80M51.98M56.33M59.84M61.11M59.68M81.04M92.51M100.88M94.14M109.91M113.87M141.81M128.44M165.04M165.45M
EBITDA (Quarter)
-42.77M-51.96M-35.78M-52.76M-42.28M-40.15M-45.46M-66.74M-62.27M-67.69M-69.16M-71.96M-105.57M-97.11M-122.37M-115.79M-113.89M-116.13M-125.28M-181.66M
Interest Expenses (Quarter)
60.68M0.20M26.07M13.48M42.54M113.62M32.23M26.46M15.51M145.78M133.49M178.02M4.98M6.55M2.90M2.55M49.38M88.72M